• AdipoGen Life Sciences offers the largest panel of ultrapotent MultimericLigands™ and highly active Mutant Proteins.
• The high activity and low endotoxin proteins are produced in mammalian cells.
• MultiPacks for big savings and bulk quantities for in vivo studies in mice are available from stock!
NEW INSIGHTS
Activation of Innate Lymphoid Cells 2 In Vivo
Works in human and mice. The biological activity of IL-33 at its receptor ST2 is rapidly terminated in the extracellular environment by its oxidation (formation of two disulfide bridges), resulting in an extensive conformational change that disrupts the ST2 binding site. Mutations at amino acids C208S/C232S protect IL-33 from oxidation and increase its activity.
LIT: E.S. Cohen, et al.; Nat. Commun. 6, ID8327 (2015)
________________________________________
Activation in vivo of Innate Lymphoid Cells 2 (ILC2) by IL-33 (oxidation resistant) (human) (rec.) (untagged) (AG-40B-0160).
Method: C57BL/6 mice were injected daily for 3 days with PBS (Figure A) or IL-33 (oxidation resistant) (human) (rec.) (untagged) (AG-40B-0160) (at 0.4µg per mouse) (Figure B). At day 4, cells from bone marrows were stained and analyzed by flow cytometry. Levels of ST2 and KLRG1 on Innate Lymphoid Cells (gated as lineage negative, CD127 positive cells) are shown. Picture courtesy of Dr G.Verdeil / Dr S. Trabanelli (Camilla Jandus Group, Department of Fundamental Oncology, University of Lausanne).
UNIQUE
IL-2 Mutant for Enhanced Cytotoxic T Cell Induction*
Compared to IL-2, the IL-2 Superkine induces superior expansion of cytotoxic CD8+ T and NK cells, leading to improved antitumor responses in vivo. IL-2 Superkine activates only poorly T regulatory cells (Tregs), meaning less toxic effects in vivo.
*LIT: AM. Levin, et al.; Nature 484, 529 (2012)
________________________________________
Binding of IL-2 Superkine (Fc) (AG-40B-0111) to IL-2Rβ (human) is increased >10 fold compared to IL-2 (human):Fc (human).
Method: IL-2Rβ (human) was coated on an ELISA plate at 1μg/ml. After blocking and washing steps, indicated concentrations of IL-2 Superkine (Fc) (AG-40B-0111) or IL-2 (human):Fc (human) (CHI-HF-21002) were added. Following incubation for 1 hour at RT, the binding was detected using an anti-human Fc antibody (HRP).
CD28/B7 Pathway – Importance in PD-1 Therapy
PD-1–targeted therapies have been a breakthrough for treating certain tumors and can rejuvenate T cells to unleash the anticancer immune response. Recently, it was shown that PD1 inhibits T cell activation by suppressing positive co-stimulation through CD28, instead of TCR itself. CD28 is required for PD-1 therapies to kill cancer cells efficiently and eliminate chronic viral infections in mice and is a critical target for PD-1 blockade.
LIT: Rescue of exhausted CD8 T cells by PD-1–targeted therapies is CD28-dependent: A.O. Kamphorst, et al.; Science 355, 1423 (2017) • T cell costimulatory receptor CD28 is a primary target for PD-1–mediated inhibition: E. Hui, et al.; Science 355, 1428 (2017)
CD279 [PD-1] (mouse):Fc (human) (rec.) (NEW) - CHI-MF-111PD1-C100
UNIQUE
MultimericFasL™ [MegaFasL™]
MultimericFasL™ simulates the natural membrane-assisted aggregation of FasL [APO-1L; CD95L; TNFSF6] in vivo. It binds to human and mouse Fas [CD95] and induces apoptosis of human Jurkat T cells at a concentration of <1ng/ml.
LIT: N. Holler, et al.; Mol. Cell. Biol. 23, 1428 (2003) | P. Greaney, et al.; Leuk. Res. 30, 415 (2006)
Oligomerization of FasL (human) efficiently triggers Jurkat cell death.
Method: Jurkat cells were treated O/N with the indicated concentrations of FasL (human) (multimeric) (rec.) (AG-40B-0130), Fc (human):FasL (human) (rec.) (AG-40B-0132), FasL (human) (rec.) (AG-40B-0001) or FasL (human) (rec.) + Enhancer (AG-44B-0001) (2 fold-dilutions, first concentration of 1000ng/ml). Cell death was quantified using PMS/MTS. The oligomeric FasL recombinant proteins (FasL (human) (multimeric), Fc (human):FasL (human) and FasL (human) + Enhancer) kill Jurkat cells at IC50 <0.2ng/ml.
THE STANDARD
MultimericCD40L™
MultimericCD40L™ very effectively mimics the natural membrane-assisted aggregation of CD40L [CD154; TNFSF5]. It is the most potent alternative to activate CD40. MultimericCD40L™ is a potent B cell activator.
LIT: C. Werner-Favre, et al.; Eur. J. Immunol. 31, 243 (2001) | C. Kaltenmeier, et al.; J. Immunol. 194, 3768 (2015)
Human MultimericCD40L™ (AG-40B-0010) does not need an enhancer to induce B cells activation.
Method: PBL cells were incubated in 96-well plates (2x105cells/well in 100μl RPMI supplemented with 10% FCS) for 24 hours at 37°C with the indicated concentration of CD40L (human) (multimeric) (rec.) (AG-40B-0010) or CD40L (human) in the presence and absence of 1μg/ml Enhancer (AG-35B-0001). Cells were washed with PBS and stained with 2μl each of CD86-PE and CD19-FITC in 50μl FACS buffer (PBS, 5% fetal calf serum, 0.02% azide) for 20 min. at 4°C in the dark. After two washes in FACS buffer, samples were then analyzed by flow cytometry.
MultimericAPRIL™
UNIQUE
Potent Angiopoietin-1 Construct
This is a soluble, stable and more potent angiopoietin-1 [Ang-1; ANGPT1] variant. The protein forms pentameric structures.
LIT: CH. Cho, et al.; PNAS 101, 5547 (2004) | HY. Shin, et al.; J. Neurosci. Res. 88, 1052 (2010) | S. Kim, et al.; J. Cell. Biochem. 114, 2513 (2013)
________________________________________
COMP (rat):Angiopoietin-1 (human) (rec.) (AG-40B-0147) binds to Tie-2 (human):Fc (human).
Method: Tie-2 (human):Fc was coated on an ELISA plate at 1μg/ml. After blocking and washing steps, indicated concentrations of COMP (rat):Angiopoietin-1 (human) (AG-40B-0147) or a Control were added. Following incubation for 1 hour at RT, the binding was detected using an anti-FLAG antibody (HRP).
BAFF, Soluble (human) (60-mer) (rec.) (highly active)
Processed human BAFF [BLyS; CD257; TNFSF13B] can either remain as a trimer, which is usual for TNF family ligands, or assemble into 60-mer composed of 20 trimers. The oligomeric form of BAFF (60-mer) mimics membrane-bound BAFF and activates all BAFF receptors (BAFF-R, TACI and BCMA) while BAFF (3-mer) only triggers BAFF-R signaling.
LIT: C. Bossen, et al.; Blood 111, 1004 (2008) | C. Bossen, et al.; Eur. J. Immunol. 41, 787 (2011) | J. Nys, et al.; PLoS One 8, e61350 (2013)
BAFF, Soluble (human) (60-mer) (AG-40B-0112) binds and activates the BCMA receptor.
Method: Jurkat T cells expressing a BCMA:Fas chimerical receptor (containing an extracellular domain of human BCMA and the intracellular domain of human Fas) were exposed for 16 hours to various concentrations of BAFF, Soluble (human) (60-mer) (AG-40B-0112). Cell viability was measured with the PMS/MTS assay.
NEW RELEASES
Highly Active DLL4 Notch Ligand Mutant
The Notch ligand delta-like protein 4 (DLL4) functions as a ligand for Notch1 and Notch4. It is induced by VEGF as a negative feedback regulator and acts to prevent overexuberant angiogenic sprouting, promoting the timely formation of a well differentiated vascular network. This mutant protein interacts with human Notch1 with >20 fold increase in affinity relative to WT DLL4.
DLL4 (human):Fc (human) (rec.) (highly active mutant) (AG-40B-0176) binds to mNotch1 with higher affinity than WT DLL4:Fc.
Method: Notch1 (mouse):Fc was coated on an ELISA plate at 1μg/ml. After blocking and washing steps, indicated concentrations of DLL4 (human):Fc (human) (highly active mutant) (AG-40B-0176) and DLL4 (human):Fc (human) WT (AG-40A-0077Y) were added. Following incubation for 1 hour at RT, the binding was detected using an anti-Notch1 (mouse) primary antibody (AG-20B-0051), following with an anti-IgG (rat) (HRP) secondary antibody.
Potent CD137L [4-1BBL] Fusion Protein
CD137L [4-1BBL; TNFSF9] is a type II transmembrane protein found on activated macrophages, dendritic cells and mature B cells. CD137L and CD137 [4-1BB] have been reported to be involved in tumor rejection, apoptosis, anti-viral immunity, diabetes and in T and B cell co-stimulation and modulation of the immune response. The Fc version of the CD137L ligand is a multimer and CD137L oligomerization has been reported to enhance its activity.
Review: B. Dharmadhikari, et al.; Oncoimmunology 5, e1113367 (2015)
Fc (human):CD137L, Soluble (human) (rec.) (AG-40B-0173) binds to human CD137.
Method: CD137 (human):Fc was coated on an ELISA plate at 1μg/ml. After blocking and washing steps, indicated concentrations of Fc (human):CD137L, Soluble (human) (AG-40B-0173) was added. Following incubation for 1 h at RT, the binding was detected using an anti-human CD137L primary antibody (AG-20A-0031), following with an anti-IgG (mouse) (HRP) secondary antibody.
Potent OX40L Protein Construct for T Cell Activation
OX40L [CD252; TNFSF4] is a membrane-expressed cytokine that belongs to the TNF ligand family. It acts as costimulator through interaction with its receptor OX40 on T cells, stimulating T cell activation, proliferation and cytokine production. OX40L is expressed on antigen presenting cells including B cells, dendritic cells, mast cells and endothelium. Fc (human):OX40L, Soluble (human) (rec.) is a high activity construct in which two trimeric OX40L ligands are artificially linked via the Fc domain of human immunoglobulin. It has been reported to activate T cell proliferation.
See more related products
NEW & UNIQUE Immune Checkpoint Receptor
CD112R
CD112R [PVRIG; Poliovirus receptor-related immunoglobulin domain-containing protein] is a new high affinity receptor of CD112/Nectin-2. It inhibits TCRmediated signals upon binding to CD112/Nectin-2. CD112R as a new regulator of the immune system may become a new attractive cancer immunotherapy target.
Visit www.adipogen.com for a Complete Panel of Immune Checkpoint Proteins & Antibodies!
Highly Active IL-36 Family Proteins
IL-36α β, γ are members of the IL-1 family with proinflammatory effects and involvement in first-line defence against microorganisms. IL-36γ is associated with skin, lung and bowel inflammation and was shown to be a specific biomarker for psoriasis.
Highly Active hIDO1 For Enzymatic Assays & Inhibitor Screenings
Plasma Cell Survival & Proliferation Blocking Antibodies
In vivo Inflammasome Inhibitor
From the Manufacturer of iNKT Stimulators
 |
Advanced Immune Regulation Reagents 2nd Edition Flyer
Including a Panel of Highly Active Proteins & Enzymes, Ig-based Chimeric Fusion Proteins with Long Circulation Half-life, Unique Blocking Antibodies
Sconto 25%
su ogni prodotto elencato sotto e su tutti quelli descritti nella brochure
Advanced Immune-Regulation Reagents
Valido fino al 31 Dicembre 2017. Non cumulabile con altri sconti. Non valido per distributori.
|